September 2nd 2022
Panelists respond to a question from Michael Wang, MD, about the role of CAR T-cell therapy in CLL, and Brian T. Hill, MD, PhD, summarizes takeaways from the TRANSCEND CLL study.
August 26th 2022
The faculty members share expert insights into treatment approaches for patients with double-refractory chronic lymphocytic leukemia.
Brian T. Hill, MD, PhD, and Matthew S. Davids, MD, MMSc, address the role of study design in CLL to highlight the importance of patient-reported QOL outcomes and matching-adjusted indirect treatment comparisons (MAICs).
August 19th 2022
Key opinion leaders in CLL review factors driving therapeutic decision-making among the available second-generation BTK inhibitors including efficacy and safety considerations.
An expert in hematologic malignancies, Catherine C. Coombs, MD, shares insights gleaned from the ALPINE clinical trial of zanubrutinib vs ibrutinib for relapsed/refractory CLL.
August 12th 2022
Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.
Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.
August 5th 2022
Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.
A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.
July 29th 2022
Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.
Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.
July 22nd 2022
Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.
A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.
July 15th 2022
Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.
Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.
March 14th 2022
Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.
March 7th 2022
A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
February 28th 2022
Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.